Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of AZD9291 with Omeprazole in Healthy Volunteers
NCT02224053Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoints: Area Under the Curve of AZD9291 at 504 hours and Maximum Plasma Concentration of AZD9291 at 504 hours. Started Sep 2014; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02224053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02224053.